Literature DB >> 9778662

Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats.

G Schulteis1, L Stinus, V B Risbrough, G F Koob.   

Abstract

Previous studies in rodents have reported that clonidine, an alpha 2-adrenergic receptor agonist, attenuated conditioned aversions to naloxone-precipitated opiate withdrawal when administered prior to each withdrawal conditioning episode. The current study was designed to determine whether clonidine could modify the expression of previously established conditioned place aversions and conditioned suppression of operant responding. Dose- and time-dependent effects of clonidine on activity and suppression of operant responding for food identified appropriate treatment parameters for subsequent studies in which rats rendered dependent on opiates through implantation of morphine pellets were tested for: (1) conditioned place aversion; and (2) conditioned suppression of operant responding for food (fixed ratio-15 schedule), in a paradigm wherein rats received four pairings of naloxone with a distinct tone and odor stimulus. Clonidine dose-dependently blocked the acquisition of both conditioned behaviors when administered prior to naloxone on each conditioning trial, but was ineffective in blocking the expression of these conditioned withdrawal signs when administered prior to the test session.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778662     DOI: 10.1016/S0893-133X(98)00036-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  12 in total

1.  Extinction of drug- and withdrawal-paired cues in animal models: relevance to the treatment of addiction.

Authors:  Karyn M Myers; William A Carlezon
Journal:  Neurosci Biobehav Rev       Date:  2010-01-28       Impact factor: 8.989

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

3.  Neurobiology of dysregulated motivational systems in drug addiction.

Authors:  Scott Edwards; George F Koob
Journal:  Future Neurol       Date:  2010-05-01

Review 4.  Neurocircuitry of addiction.

Authors:  George F Koob; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

5.  Corticotropin-releasing factor (CRF) and α 2 adrenergic receptors mediate heroin withdrawal-potentiated startle in rats.

Authors:  Paula E Park; Leandro F Vendruscolo; Joel E Schlosburg; Scott Edwards; Gery Schulteis; George F Koob
Journal:  Int J Neuropsychopharmacol       Date:  2013-04-16       Impact factor: 5.176

6.  Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys.

Authors:  S Stevens Negus; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

7.  Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats.

Authors:  George Zislis; Tina V Desai; Melissa Prado; Hina P Shah; Adrie W Bruijnzeel
Journal:  Neuropharmacology       Date:  2007-09-23       Impact factor: 5.250

8.  Conditional deletion of the NMDA-NR1 receptor subunit gene in the central nucleus of the amygdala inhibits naloxone-induced conditioned place aversion in morphine-dependent mice.

Authors:  Michael J Glass; Deborah M Hegarty; Martin Oselkin; Laarni Quimson; Samantha M South; Qinghao Xu; Virginia M Pickel; Charles E Inturrisi
Journal:  Exp Neurol       Date:  2008-05-20       Impact factor: 5.330

Review 9.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

Review 10.  Brain stress systems in the amygdala and addiction.

Authors:  George F Koob
Journal:  Brain Res       Date:  2009-03-28       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.